List of Excipients in Branded Drug INDOCIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Iroko Pharmaceuticals LLC	INDOCIN	indomethacin	42211-101	ALCOHOL
Iroko Pharmaceuticals LLC	INDOCIN	indomethacin	42211-101	HYDROCHLORIC ACID
Iroko Pharmaceuticals LLC	INDOCIN	indomethacin	42211-101	SODIUM HYDROXIDE
Iroko Pharmaceuticals LLC	INDOCIN	indomethacin	42211-101	SORBIC ACID

Generic Drugs Containing INDOCIN

Company	Ingredient	NDC	Excipient
Iroko Pharmaceuticals LLC	indomethacin	42211-102	BUTYLATED HYDROXYANISOLE
Iroko Pharmaceuticals LLC	indomethacin	42211-102	BUTYLATED HYDROXYTOLUENE
Iroko Pharmaceuticals LLC	indomethacin	42211-102	EDETIC ACID
Iroko Pharmaceuticals LLC	indomethacin	42211-102	GLYCERIN

What are the Most Frequently-Used Excipients in INDOCIN?

# Of NDCs	Excipient
2	BUTYLATED HYDROXYANISOLE
2	BUTYLATED HYDROXYTOLUENE
2	EDETIC ACID
2	GLYCERIN

Excipient Strategy and Commercial Opportunities for Indocin (Indomethacin)

Last updated: February 26, 2026

What is the current excipient profile for Indocin?

Indocin (indomethacin) formulations primarily contain excipients such as lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, colloidal silicon dioxide, magnesium stearate, and talc. These excipients serve as fillers, binders, disintegrants, glidants, and lubricants, supporting tablet manufacturability and stability.

How does excipient selection influence Indocin's bioavailability and stability?

Indomethacin's bioavailability (40-60%) depends on formulation factors influenced by excipients. For example, disintegrants like sodium starch glycolate accelerate dissolution, improving absorption. Stabilizers and antioxidants (e.g., ascorbic acid, polyols) reduce oxidation, extending shelf life. The choice of excipients impacts performance, patient tolerability, and manufacturing consistency.

What are the trends in excipient development for NSAID formulations?

Recent trends shift toward enhancing bioavailability through nanoparticle or amorphous formulations, requiring novel excipients or carriers:

• Surfactants to improve solubility
• Cyclodextrins for complexation
• Polymer-based matrix systems for sustained release

These developments target reducing gastrointestinal adverse effects, a common issue with indomethacin, and expanding the drug's application scope.

What commercial opportunities exist through excipient innovation?

Opportunities arise in three areas:

1. Developing Better Dissolution Enhancers

Formulating indigestion-resistant or faster-dissolving tablets with excipients like superdisintegrants or solubilizers (e.g., cyclodextrins) can address bioavailability issues and improve patient compliance.

2. Creating Novel Delivery Systems

Using excipients for controlled-release formulations (matrix polymers like ethylcellulose) offers opportunities to reduce dosing frequency, improve adherence, and minimize gastrointestinal irritation.

3. Expanding Formulation Portfolios

Introducing alternative dosage forms—solutions, suspensions, or patches—can cater to pediatric, geriatric, or specialized populations. Excipient strategies here focus on stabilizers, suspending agents, and skin permeation enhancers.

How do excipient regulations influence commercial strategies?

Regulatory bodies (FDA, EMA) impose strict safety and quality requirements on excipients, emphasizing Good Manufacturing Practice (GMP). Innovation must comply with pharmacopoeial standards and demonstrate excipient safety, especially for new or functional excipients.

What are the intellectual property considerations?

Novel excipient combinations or delivery systems can secure patent protection. Companies can patent formulation patents, such as controlled-release matrices or co-crystals with specific excipients, creating barriers to generics and enabling premium pricing.

What is the competitive landscape?

Major pharmaceutical firms focus on refining excipient systems for NSAID formulations to enhance efficacy, tolerability, and patient-centered dosing. Collaborations between formulators and excipient manufacturers are common, with companies like Meggle, BASF, and Ashland developing specialized excipients for NSAIDs.

Summary of key formulation challenges

Challenge	Potential Excipient Solution	Impact
Gastrointestinal irritation	Coating agents, pH modifiers, buffered excipients	Reduced adverse effects, improved tolerability
Poor bioavailability	Surfactants, cyclodextrins, nanocarriers	Enhanced absorption, faster onset
Stability concerns	Antioxidants, desiccants	Extended shelf life
Variable dissolution profiles	Superdisintegrants, controlled-release polymers	Consistent therapeutic effect

Key Takeaways

• Excipient choice directly impacts Indocin’s pharmacokinetics, stability, and tolerability.
• Innovation in excipients can facilitate new formulations, including sustained-release or novel delivery routes.
• Regulatory compliance and intellectual property are critical to commercial success.
• Partnerships with excipient suppliers can accelerate development and differentiation.
• Addressing gastrointestinal side effects through excipient strategies can expand Indocin’s market acceptance.

FAQs

1. What excipients are most critical for Indocin formulations?

Lactose monohydrate, microcrystalline cellulose, and sodium starch glycolate mainly influence manufacturability and dissolution. Stabilizers and antioxidants maintain stability.

2. Can new excipients improve Indocin’s gastrointestinal tolerability?

Yes. Coatings with barrier agents or pH modifiers, or incorporating buffering agents, can reduce GI irritation.

3. Are there formulation strategies to enhance indomethacin’s bioavailability?

Formulation approaches include using surfactants, cyclodextrins, or nanoparticle systems to improve solubility and absorption.

4. What regulatory considerations affect excipient innovation?

Any novel excipients or excipient combinations must meet safety standards regulated by agencies like FDA and EMA, including toxicology data and GMP compliance.

5. Which commercial avenues exist for innovating Indocin formulations?

Developing controlled-release tablets, fast-dissolving forms, or targeted delivery systems represent primary opportunities. Patent protection on these innovations can yield competitive advantages.

---

References

[1] Food and Drug Administration. (2021). Guidance for Industry: Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients. FDA.